Charles Schwab
ACTU

Charles Schwab’s Actuate Therapeutics ACTU Stock Holding History

Charles Schwab’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Sell
11,146
-12,695
-53% -$52.6K ﹤0.01% 3444
2025
Q4 		$146K Buy
23,841
+9,076
+61% +$62.3K ﹤0.01% 3373
2025
Q3 		$98.8K Hold
14,765
– – ﹤0.01% 3394
2025
Q2 		$90.2K Buy
+14,765
New +$129K ﹤0.01% 3421

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab's ACTU Position: Q1 2026 in Review

Charles Schwab reduced its Actuate Therapeutics (ACTU) stake by 53% in Q1 2026, selling an estimated $52.6K and leaving 11,146 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

Charles Schwab first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $146K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Charles Schwab held 11,146 shares of Actuate Therapeutics worth $30.5K as of Q1 2026.
  • Charles Schwab sold 12,695 Actuate Therapeutics shares in Q1 2026, an estimated $52.6K.
  • Actuate Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3444 holding.
  • Charles Schwab first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Charles Schwab's Actuate Therapeutics position peaked at $146K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.